Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals Intl Inc (VRX), Actavis Inc (ACT): How Would A Combined Company Look?

In all likelihood, such a merger would involve a cash-for-stock purchase or tender offer. As the acquiring firm, Valeant would need to use a combination of leverage and cash to finance the deal. This could prove problematic. Since Valeant is highly leveraged at the moment, it might find it difficult to put together the financing necessary to set the transaction in motion. Indeed, the company is obviously looking for the best possible deal. During the first week of May, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s management team quashed the early exuberance that surrounded the deal by announcing that the talks had hit a serious price-related speed bump. Neither company has indicated if he talks might restart. Likewise, no timetable for completion has been set.

How the Combined Company Might Look

As noted, the combined company would boast revenue of nearly $10 billion a year and enjoy a major foothold in the booming dermatology products market. Indeed, it would hold the rights to several key brand-name drugs like AndroGel and AndroDerm as well as the formulas for many popular generic compounds. This would be exciting for investors who believe in the potential for further expansion in the dermatological sub-field. On the other hand, the combined company would be heavily indebted and might still be recovering from a slew of earlier acquisitions. Despite raising full-year profit guidance figures, both Valeant and Actavis have recently reported acquisition-related charges.

Long-Term Outlook and Possible Plays

In sum, the dermatology sub-field has exhibited solid growth on the strength of popular acne treatments and topical hormone therapy creams. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Actavis Inc (NYSE:ACT) have both profited from this growth. While the two companies engage in other activities, their core strengths lie here. If they ultimately merge, the combined firm could be a powerful force in this space; however, this deal is by no means assured. Investors who remain skeptical of the deal’s timely completion would do well to remain on the sidelines for the time being. Alternatively, well-researched long positions in Actavis may pay off handsomely in the event that the merger does go through as planned. In either case, these two companies bear watching.

The article Following Up an Acquisition With an Even Larger Merger? originally appeared on Fool.com and is written by Mike Thiessen.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.